Patents by Inventor David Mendel

David Mendel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8156355
    Abstract: A method and system for reducing power consumption in a programmable logic device (PLD) is provided. The power consumption may be reduced by preferably continually considering power consumption as a factor in circuit design during the technology mapping, routing, and period following routing of the programmable logic device.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: April 10, 2012
    Assignee: Altera Corporation
    Inventors: David Mendel, Vaughn Betz
  • Publication number: 20110294792
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Application
    Filed: August 9, 2011
    Publication date: December 1, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • Patent number: 8058425
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: November 15, 2011
    Assignee: Eli Lilly and Company
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • Publication number: 20110207721
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Application
    Filed: May 4, 2011
    Publication date: August 25, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • Patent number: 7700628
    Abstract: This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. An example of a compound of formula (I) is (a).
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: April 20, 2010
    Assignee: Eli Lilly and Company
    Inventors: Ankush Baburao Argade, Theodore Goodson, Jr., David Kent Herron, Sajan Joseph, Salvatore Donato Lepore, Angela Lynn Marquart, John Joseph Masters, David Mendel, Leander Merritt, Andrew Michael Ratz, Gerald Floyd Smith, Anne Louise Tebbe, Michael Robert Wiley, Ying Kwong Yee
  • Patent number: 7666879
    Abstract: The present invention provides compounds that are inhibitors of VEGF-R2 of the formula: (I) and methods of using these compounds.
    Type: Grant
    Filed: February 23, 2006
    Date of Patent: February 23, 2010
    Assignee: Eli Lilly and Company
    Inventors: David Anthony Barda, Timothy Paul Burkholder, Joshua Ryan Clayton, Yan Hao, James Robert Henry, John Monte Knobeloch, Johnathan Alexander McLean, David Mendel, Mark Edward Rempala, Zhao-Qing Wang, Yvonne Yee Mai Yip, Boyu Zhong
  • Patent number: 7666866
    Abstract: This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.
    Type: Grant
    Filed: November 15, 2005
    Date of Patent: February 23, 2010
    Assignee: Eli Lilly and Company
    Inventors: Jeffry Bernard Franciskovich, David Kent Herron, Valentine Joseph Klimkowski, Angela Lynn Marquart, John Joseph Masters, David Mendel, Andrew Michael Ratz, Gerald Floyd Smith, Michael Robert Wiley, Ying Kwong Yee
  • Patent number: 7615568
    Abstract: This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor (I).
    Type: Grant
    Filed: April 13, 2004
    Date of Patent: November 10, 2009
    Assignee: Eli Lilly and Company
    Inventors: Jeffry Bernard Franciskovich, David Kent Herron, Jared Harris Linebarger, Angela Lynn Marquart, John Joseph Masters, David Mendel, Leander Merritt, Andrew Michael Ratz, Gerald Floyd Smith, Leland Otto Weigel, Michael Robert Wiley, Ying Kwong Yee
  • Patent number: 7594208
    Abstract: Techniques for optimizing the placement and synthesis of a circuit design on a programmable integrated circuit are provided. The performance of a circuit design is analyzed after it has been compiled with different values for selected input parameters. The input parameter values that produce the best results for an output metric are then chosen to synthesis and place the circuit design on the programmable integrated circuit. In one embodiment, the values of the output metrics are averaged for all test compiles that share the same input parameters, but different seeds. In another embodiment, the compile with the best output metrics, as determined by the user, are selected. These techniques allow a user to automatically trade off compile-time to get a better-optimized circuit.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: September 22, 2009
    Assignee: Altera Corporation
    Inventors: Terry Borer, Ian Chesal, James Schleicher, David Mendel, Mike Hutton, Boris Ratchev, Yaska Sankar, Babette van Antwerpen, Gregg Baeckler, Richard Yuan, Stephen Brown, Vaughn Betz, Kevin Chan
  • Publication number: 20090227622
    Abstract: The present invention provides compounds that are inhibitors of VEGF-R2 of the formula: (I) and methods of using these compounds.
    Type: Application
    Filed: February 23, 2006
    Publication date: September 10, 2009
    Inventors: David Anthony Barda, Timothy Paul Burkholder, Joshua Ryan Clayton, Yan Hao, James Robert Henry, John Monte Knobeloch, Johnathan Alexander Mclean, David Mendel, Mark Edward Rempala, Zhao-Qing Wang, Yvonne Yee Yip, Boyu Zhong
  • Publication number: 20090227566
    Abstract: This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. An example of a compound of formula (I) is (a).
    Type: Application
    Filed: November 10, 2005
    Publication date: September 10, 2009
    Inventors: Ankush Baburao Argade, Theodore Goodson, JR., David Kent Herron, Sajan Joseph, Salvatore Donato Lepore, Angela Lynn Marquart, John Joseph Masters, David Mendel, Leander Merritt, Andrew Michael Ratz, Gerald Floyd Smith, Anne Lousie Tebbe, Michael Robert Wiley, Ying Kwong Yee
  • Publication number: 20090138696
    Abstract: A method and system for reducing power consumption in a programmable logic device (PLD) is provided. The power consumption may be reduced by preferably continually considering power consumption as a factor in circuit design during the technology mapping, routing, and period following routing of the programmable logic device.
    Type: Application
    Filed: December 5, 2008
    Publication date: May 28, 2009
    Applicant: Altera Corporation
    Inventors: David Mendel, Vaughn Betz
  • Publication number: 20090105229
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Application
    Filed: December 12, 2008
    Publication date: April 23, 2009
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel
  • Patent number: 7511066
    Abstract: This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: March 31, 2009
    Assignee: Eli Lilly and Company
    Inventors: Jeffry Bernard Franciskovich, Theodore Goodson, Jr., David Kent Herron, Angela Lynn Marquart, John Joseph Masters, David Mendel, Leander Merritt, Andrew Michael Ratz, Gerald Floyd Smith, Michael Robert Wiley, Ying Kwong Yee
  • Patent number: 7509618
    Abstract: A method for designing systems on field programmable gate arrays (FPGAs) includes caching design information from a compilation of a system design. The design information is utilized in a compilation of a subsequent system design.
    Type: Grant
    Filed: May 12, 2004
    Date of Patent: March 24, 2009
    Assignee: Altera Corporation
    Inventors: Michael Hutton, Yean-Yow Hwang, David Mendel
  • Publication number: 20090062271
    Abstract: This application relates to a compound of formula I (or a pharmaceutically acceptable salt of the compound) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.
    Type: Application
    Filed: November 15, 2005
    Publication date: March 5, 2009
    Applicant: Eli Lilly And Company
    Inventors: Jeffry Bernard Franciskovich, David Kent Herron, Valentine Joseph Klimkowski, Angela Lynn Marquart, John Joseph Masters, David Mendel, Andrew Michael Ratz, Gerald Floyd Smith, Michael Robert Wiley, Ying Kwong Yee
  • Patent number: 7467314
    Abstract: A method and system for reducing power consumption in a programmable logic device (PLD) is provided. The power consumption may be reduced by preferably continually considering power consumption as a factor in circuit design during the technology mapping, routing, and period following routing of the programmable logic device.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: December 16, 2008
    Assignee: Altera Corporation
    Inventors: David Mendel, Vaughn Betz
  • Patent number: 7467310
    Abstract: A method and system for reducing power consumption in a programmable logic device (PLD) is provided. The power consumption may be reduced by preferably continually considering power consumption as a factor in circuit design during the synthesis, placement, routing, and period following routing of the programmable logic device.
    Type: Grant
    Filed: September 19, 2007
    Date of Patent: December 16, 2008
    Assignee: Altera Corporation
    Inventor: David Mendel
  • Patent number: 7449457
    Abstract: This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: November 11, 2008
    Assignee: Eli Lilly and Company
    Inventors: David Kent Herron, Sajan Joseph, Angela Lynn Marquart, John Joseph Masters, David Mendel, Gerald Floyd Smith, Anne Louise Tebbe, Philip Parker Waid, Michael Robert Wiley, Ying Kwong Yee
  • Publication number: 20080108594
    Abstract: This application relates to a compound of formula I (or a pro-drug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor (I).
    Type: Application
    Filed: April 13, 2004
    Publication date: May 8, 2008
    Applicant: Eli Lilly and Company
    Inventors: Jeffry Bernard Franciskovich, David Kent Herron, Jared Harris Linebarger, Angela Lynn Marquart, John Joseph Masters, David Mendel, Leander Merritt, Andrew Michael Ratz, Gerald Floyd Smith, Leland Otto Weigel, Michael Robert Wiley, Ying Kwong Yee